New Hope for GI Cancers: How Novel Therapies and Pharmacist Expertise are Reshaping Treatment

Gastrointestinal (GI) cancers, which account for nearly a quarter of all cancer-related deaths globally, have long presented a formidable challenge to clinicians. However, a recent review published in Clinical Advances in Hematology & Oncology offers a promising look at a rapidly evolving treatment landscape. The review highlights a new generation of targeted therapies and expanded drug indications for colorectal and pancreatic cancers, signaling a shift away from traditional chemotherapy and underscoring the critical, expanding role of pharmacists in patient care.

The New Front Line of GI Cancer Therapy

The review summarized several key regulatory approvals and clinical developments that are reshaping how GI cancers are treated. These advancements include oral tyrosine kinase inhibitors and HER2-targeted therapies, which provide new hope for patients with advanced-stage disease where options were previously limited.

Fruquintinib (Fruzaqla; Takeda): Approved by the FDA in 2023, fruquintinib is a new oral VEGFR inhibitor. Its mechanism of action involves blocking tumor angiogenesis—the process by which new blood vessels are formed to feed a tumor. This therapy is specifically indicated for refractory metastatic colorectal cancer, offering a new and crucial option for patients who have already undergone multiple failed treatments.
Tucatinib and Trastuzumab Combination: A significant advancement is the expanded indication for the combination of tucatinib (Tukysa; Pfizer) and trastuzumab (Enhertu; Daiichi-Sankyo, AstraZeneca). This regimen, which has been a cornerstone of treatment for HER2-positive breast cancer, is now approved for HER2-positive metastatic colorectal cancer. This offers a valuable, non-cytotoxic alternative for a select group of patients, potentially reducing the severe side effects associated with traditional chemotherapy.
Trifluridine-tipiracil (Lonsurf; Taiho Oncology): Already a cornerstone of late-line colorectal cancer management, new data continues to support the use of trifluridine-tipiracil in combination strategies. This further solidifies its role in providing prolonged benefit for patients with limited options.

The Pharmacist’s Crucial Battle Strategy

The shift toward these complex, targeted oral agents places pharmacists at the forefront of patient management. The review emphasizes that pharmacists across all practice settings—from outpatient clinics to emergency departments—have significant responsibilities in ensuring patient safety and treatment efficacy.

Adherence and Adverse Effect Management: Oral agents like fruquintinib and trifluridine-tipiracil require meticulous counseling. Pharmacists are essential in educating patients on proper adherence, managing common toxicities such as hypertension and hand-foot syndrome, and ensuring they understand the cycle-based dosing schedules.
Drug-Drug Interaction Vigilance: With medications like tucatinib being a CYP3A4 substrate, pharmacists must exercise caution and conduct thorough medication reconciliations to identify potential drug-drug interactions, particularly with other common outpatient medications.
Comprehensive Monitoring: Pharmacists are vital in monitoring for potential complications. This includes a close watch on laboratory results for neutropenia, liver enzymes, and blood pressure, especially in older patients who may be at increased risk due to diminished organ function or polypharmacy.
Patient Education and Interdisciplinary Collaboration: Pharmacists are uniquely positioned to help patients distinguish between manageable side effects and more serious issues that require immediate medical intervention, such as febrile neutropenia or severe diarrhea. Their expertise is also crucial in emergency settings to recognize and manage complications like hypertensive crises or chemotherapy-induced dehydration.

A Call for Continuous Learning

The authors conclude that as GI oncology paradigms continue to evolve, it is paramount for all healthcare professionals, and especially pharmacists, to stay continuously updated on emerging therapies, expanded indications, and new clinical guidelines. By embracing their role as medication experts and collaborating effectively with other members of the healthcare team, pharmacists can ensure that patients receive the safest, most effective, and personalized care possible in this rapidly advancing field.